CTNI-43. COMBINATION OF TROFOSFAMIDE PLUS ETOPOSIDE IN RECURRENT ADULT-TYPE DIFFUSE GLIOMAS

Abstract Disease relapse almost inevitably occurs in patients with adult-type diffuse glioma. Standard of care treatment options at tumor are still not well defined. Few studies indicate that the combination trofosfamide plus etoposide (T/E) may be feasible pediatric glioblastoma patients. We collected clinicopathological data from adult glioma treated Trofosfamide (100mg/m2/day) and Etoposide (25mg/m2/day) for a minimum four weeks Division Clinical Neurooncology University Hospital Essen. T/E was administered orally “one week on, one off” scheme. A cohort receiving empiric investigators’ discretion balanced entity canonical prognostic factors served as control. toxicity it pertained to CTCAE (Common Terminology Criteria Adverse Events, version 5.0) survival explore putative efficacy.A total 33 were eligible this analysis. In IDH wild-type (n = 18) subgroup, median progression-free (3.8 months versus 2.9 months, HR: 2.09, 95% CI: 1.010-4.312, p 0.0227; PFS-6: 39% 6%) overall (10.4 5.7 3.05, 1.393-6.655, 0.0008) significantly prolonged compared control cohort. multivariable Cox regression analysis, emerged statistically significant marker regarding survival. observed high-grade adverse events (CTCAE grade III or higher) 21 (64%) all recurrent hematotoxicity comprising most 18, 86%; Lymphopenia: n=13, 62%). This study provides first indication is safe gliomas associated wildtype glioblastoma. Our provide reasonable rationale follow-up larger prospective controlled trial.